Evidence map›Paper›PMID 21455295›Full record

ArticlePloS one2011

Small-molecule inhibitor leads of ribosome-inactivating proteins developed using the doorstop approach.

Yuan-Ping Pang, Jewn Giew Park, Shaohua Wang, Anuradha Vummenthala, Rajesh K Mishra, John E McLaughlin, Rong Di, Jennifer Nielsen Kahn, Nilgun E Tumer, Laszlo Janosi and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Baicalin inhibits the lethality of Shiga-like toxin 2 in mice.Antimicrobial agents and chemotherapy · 2015
    Article
  11. Article
  12. Article
  13. Targeting ricin to the ribosome.Toxicon : official journal of the International Society on Toxinology · 2013
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yuan-Ping PangComputer-Aided Molecular Design Laboratory, Mayo Clinic, Rochester, Minnesota, United States of America. pang@mayo.edu
Jewn Giew Park
Shaohua Wang
Anuradha Vummenthala
Rajesh K Mishra
John E McLaughlin
Rong Di
Jennifer Nielsen Kahn
Nilgun E Tumer
Laszlo Janosi
Jon Davis
Charles B Millard
Mayo Clinic in Florida · USRutgers, The State University of New Jersey · USWalter Reed Army Institute of Research · USMayo Clinic in Arizona · US

Funding

What makes ricin ToxicR01AI072425 · NIAID · RUTGERS, THE STATE UNIV OF N.J. · PI TUMER, NILGUN E · 2007 to 2021
$5.8M
Optimization of Small-Molecule Inhibitors of Shiga and Ricin ToxinsU01AI082120 · NIAID · MAYO CLINIC ROCHESTER · PI PANG, YUAN-PING · 2009 to 2012
$3.0M
NIAID NIH HHS 1U01AI082120-01NIAID NIH HHS R01 AI072425NIAID NIH HHS R01AI072425NIAID NIH HHS U01 AI082120
6 · The paper itself

Abstract

Ribosome-inactivating proteins (RIPs) are toxic because they bind to 28S rRNA and depurinate a specific adenine residue from the α-sarcin/ricin loop (SRL), thereby inhibiting protein synthesis. Shiga-like toxins (Stx1 and Stx2), produced by Escherichia coli, are RIPs that cause outbreaks of foodborne diseases with significant morbidity and mortality. Ricin, produced by the castor bean plant, is another RIP lethal to mammals. Currently, no US Food and Drug Administration-approved vaccines nor therapeutics exist to protect against ricin, Shiga-like toxins, or other RIPs. Development of effective small-molecule RIP inhibitors as therapeutics is challenging because strong electrostatic interactions at the RIP•SRL interface make drug-like molecules ineffective in competing with the rRNA for binding to RIPs. Herein, we report small molecules that show up to 20% cell protection against ricin or Stx2 at a drug concentration of 300 nM. These molecules were discovered using the doorstop approach, a new approach to protein•polynucleotide inhibitors that identifies small molecules as doorstops to prevent an active-site residue of an RIP (e.g., Tyr80 of ricin or Tyr77 of Stx2) from adopting an active conformation thereby blocking the function of the protein rather than contenders in the competition for binding to the RIP. This work offers promising leads for developing RIP therapeutics. The results suggest that the doorstop approach might also be applicable in the development of other protein•polynucleotide inhibitors as antiviral agents such as inhibitors of the Z-DNA binding proteins in poxviruses. This work also calls for careful chemical and biological characterization of drug leads obtained from chemical screens to avoid the identification of irrelevant chemical structures and to avoid the interference caused by direct interactions between the chemicals being screened and the luciferase reporter used in screening assays.

Indexed as

AnimalsCell Line, TumorMiceMolecular StructurePolynucleotidesRibosome Inactivating ProteinsRicinShiga Toxin 2PolynucleotidesRibosome Inactivating ProteinsRicinShiga Toxin 2

Identifiers

PMID21455295
PMCPMC3063779
OpenAlexW2019275411

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.